The perspective article “LifeTime and improving European healthcare through cell-based interceptive medicine” was published in Nature today. The LifeTime Initiative consists of experts from varied disciplines from over ninety research institutes from all over the EU. The initiative aims to develop and integrate novel technologies such as patient-derived experimental disease models, single-cell multi-omics, high content imaging and artificial intelligence to address the current medical challenges and incorporate them into regular laboratory and clinical workflows resulting in a great benefit for healthcare providers and patients alike.